TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04165967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of TIL Transfer with anti-PD-1 Therapy and low dose IL-2
Description: The study uses a personalized IMP, i.e. TIL product and in combination with IL-2 treatment and nivolumab.~Day 0: Autologous TIL: (minimum 5 x 109 and up to a maximum of 2 x 1011 lymphocytes) administered intravenously over 20 to 30 minutes.~Day 0: Interleukin-2 (Proleukin): 125.000 IU/kg/day s.c. for maximum 12 days as inpatients with a 2 days break after the first 4-5 doses (maximum 10 days dosing). Actual body weight will be used in calculating the dose of interleukin-2.~Starting Day 14: Nivolumab application 240 mg i.v. over 30 minutes ever 2 weeks with a maximum to 2 years, or until disease progression or inacceptable toxicity.
Study: NCT03071081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOP1288
Description: Oral TOP1288
Study: NCT03176173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunotherapy (physician's choice for standard of care immunotherapy)
Description: Continue regular medical care immunotherapy. Other than being an anti-PD-1 or anti-PD-L1 immunotherapy, the agent, dose, and schedule is not specified by protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy (physician's choice for standard of care immunotherapy)
Description: Continue regular medical care immunotherapy. Other than being an anti-PD-1 or anti-PD-L1 immunotherapy, the agent, dose, and schedule is not specified by protocol.
Study: NCT03071081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOP1288
Description: Oral TOP1288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOP1288
Description: Oral TOP1288

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to TOP1288
Description: Oral placebo to TOP1288

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to TOP1288
Description: Oral placebo to TOP1288

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to TOP1288
Description: Oral placebo to TOP1288
Study: NCT00570882

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib 4/2
Description: Sunitinib 50 mg PO 4 weeks followed by 2 week rest
Study: NCT03050203

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: custom pack
Description: Preparation of the surgical field using a custom pack. The use of a custom pack provides much of the material provided for the preparation of the surgical field with a single opening of the package , reducing the risk of contamination of the material.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: The scrub nurse prepares the surgical field opening all the sterile packs it deems necessary for the surgery
Study: NCT03512951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital signal processing algorithms
Description: The intervention consists in applying five processing on some recorded speech signals. In particular, the processing performed by one specific algorithm is compared against the four other. The applied processing is supposed to restore sound externalization (expected audio-visual fusion).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital signal processing algorithms
Description: The intervention consists in applying five processing on some recorded speech signals. In particular, the processing performed by one specific algorithm is compared against the four other. The applied processing is supposed to restore sound externalization (expected audio-visual fusion).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital signal processing algorithms
Description: The intervention consists in applying five processing on some recorded speech signals. In particular, the processing performed by one specific algorithm is compared against the four other. The applied processing is supposed to restore sound externalization (expected audio-visual fusion).
Study: NCT05320341

Intervention type: PROCEDURE
Intervention: TIVA
Description: During the anesthesia maintenance of the TIVA group, 3 μg.kg-1 fentanyl, 0.01-0.05 mg.kg-1 midazolam, and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40 and 60, approximately once every 45 minutes.

Intervention type: PROCEDURE
Intervention: SEVO
Description: During the anesthesia maintenance of the SEVO group, 2-3% sevoflurane (1-2 MAC), 3 μg.kg-1 fentanyl and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40-60.
Study: NCT02664233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile and connected health
Description: Patients will use a smart phone and a fitness tracker for self-monitoring of diet and physical activity for 3 months; 3) Smart phones will provide feedback with graphical presentation of self-monitored information to patients; 4) Patient self-monitored information will be integrated into Chronicle Diabetes, so that educators will be able to view this information and give feedback in a follow-up visit.
Study: NCT02823652

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard genetic education
Description: Undergo usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Counseling
Description: Complete remote counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Testing
Description: Undergo germline testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Complete on-line genetic education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT03077321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE plus Peer Mentor
Description: A parent who has completed the standard CARE program will be recruited to be a peer mentor. The peer mentor will attend the CARE training for group leaders and will also be trained in motivational interviewing. These skills will then be used strategically in weekly phone discussions between the peer mentor and parent about practicing the CARE parenting skills in the home setting and planning for attending the 6 training sessions. The parent mentor will co-facilitate the CARE groups in the peer mentor arm along with 2 additional CARE therapists. The peer mentor will also call the parents in the peer mentor arm before each session to discuss progress on homework, and to address barriers for program attendance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CARE
Description: CARE involves 6 weekly 90-minute sessions administered to 6-10 parents by 2 therapists. The initial phase focuses on developing parenting skills aimed at increasing attention to children's pro-social behaviors while ignoring minor attention seeking misbehaviors. The second phase teaches techniques for giving children effective commands in order to set age-appropriate limits and increase compliance. Children do not attend the training but parents are expected to practice the skills with their children between sessions.
Study: NCT03656874

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Description: The clinical decision support will provide clinical practice guideline-supported, evidence-based, and personalized scripts that are tailored based on patients' self-reported smoking attributes to deliver interventions consistent with the standard of care
Study: NCT00788502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healing Touch

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Desensitization Therapy
Study: NCT04158960

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Equine-assisted activities
Description: Participants performed riding-related activities on and off of a horse once per week for 8 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GaitWay program
Description: Participants performed riding-related activities on and off of a horse, along with brain-building activities including balance tasks, swinging, spinning, music therapy, and sensory tasks, all once per week for 8 weeks
Study: NCT02023736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systemic Therapy Inventory of Change (STIC)
Description: The STIC is a computerized measurement and feedback system for use in psychotherapy. The measurement system consists of weekly questionnaires, completed on the computer, that target symptoms and functioning in a variety of domains of a clients life (e.g., individual symptoms, couple functioning, family functioning, relationship with children). The feedback system consists of a web-portal where therapists may access their clients' STIC responses, for the purposes of planning treatment, assessing progress, and discussing change with clients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Clients receive psychotherapy treatment as planned and implemented by their psychotherapists. Exact type of treatment varies by therapist and according to client need.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Clients receive psychotherapy treatment as planned and implemented by their psychotherapists. Exact type of treatment varies by therapist and according to client need.
Study: NCT01475084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryobiopsy (Autoclavable cryoprobe 20416-032 (ERBE, Germany) Flexible FB-55CD-1 Olympus forceps
Description: The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch for 3 seconds. The frozen tissue is going to be extracted by gently pulling of the probe. The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. The biopsy sample will be released from the probe by thawing in the saline.~Forceps biopsy will be performed on usual way.
Study: NCT00534014

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C
Description: Arm A = 0 mg Vitamin C, Arm B = 250 mg Vitamin C, Arm C = 500 mg Vitamin C, Arm D = 1000 mg Vitamin C
Study: NCT02498717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GameReady
Description: Cryotherapy and compression
Study: NCT00534014

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Arm A = 0 mg Vitamin C, Arm B = 250 mg Vitamin C, Arm C = 500 mg Vitamin C, Arm D = 1000 mg Vitamin C

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Arm A = 0 mg Vitamin C, Arm B = 250 mg Vitamin C, Arm C = 500 mg Vitamin C, Arm D = 1000 mg Vitamin C

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Arm A = 0 mg Vitamin C, Arm B = 250 mg Vitamin C, Arm C = 500 mg Vitamin C, Arm D = 1000 mg Vitamin C
Study: NCT04058574

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proprioception measurement on isokinetic dynamometer
Description: Proprioception measurement on isokinetic dynamometer using joint position sense (JPS) and the threshold to detection of passive motion (TTDPM)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Proprioception measurement on isokinetic dynamometer
Description: Proprioception measurement on isokinetic dynamometer using joint position sense (JPS) and the threshold to detection of passive motion (TTDPM)
Study: NCT01521065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRay
Description: Approved dose of Anti-VEGF injection given at Day 0 followed by treatment with 16 Gy dose of IRay up to 14 days later.
Study: NCT00885521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 8 week, twice weekly exercise program with endurance and upper and lower limb strength training
Study: NCT01330420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Response Resiliency Program for Depression
Description: The program combines lecture, skills training, symptom monitoring, and group sharing aimed at preparing patients to take active roles in managing their own health. Elements of the program include:~* Elicitation of the relaxation response through techniques such as diaphragmatic breathing and mindfulness.~* Examination and reversal of negative thought patterns.~* Physical movement, including stretching and yoga.~* Healthy eating and other positive lifestyle behaviors.~* Goal setting.
Study: NCT04188314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: The intervention group will receive desflurane for maintenance of anaesthesia, and the quality of recovery score will be compared post-operatively with the control group who received isoflurane.
Study: NCT02498717

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RICE
Description: SOC ice and elevation
Study: NCT04188314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: The control group will receive Isoflurane for maintenance of anesthesia. The quality of recovery score will be compared post-operatively with patients in the intervention group who received desflurane.
Study: NCT02466230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Active repetitive transcranial magnetic stimulation for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
Study: NCT01565850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF
Description: DRV 800 mg/COBI 150 mg/FTC 200 mg/TAF 10 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DRV
Description: DRV 800 mg (2 × 400 mg tablets) administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COBI
Description: COBI 150 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: FTC 200 mg/TDF 300 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D/C/F/TAF Placebo
Description: D/C/F/TAF placebo tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV Placebo
Description: DRV placebo tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COBI Placebo
Description: COBI placebo tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF Placebo
Description: FTC/TDF placebo tablet administered orally once daily
Study: NCT03425734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The drug will be prepared in 50 ml saline 0.5 ml DEX (100mc/ml +49.5 cc saline 1ml=1mg), and the dose will be calculated according to body weight.
Study: NCT02882672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Doing exercise at 60-85% of maximal heart rate, lasted 45-60 minutes and included a 10-minute warm-up, 40 minutes of aerobic exercises, consisting of stationary cycling, walking and/or jogging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: They did not do ant exercise training during 8 weeks.
Study: NCT04178161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser treatment
Description: Iontophoresis of methylene blue is used to identify the sweat glands. An image guided fractional erbium laser is used to specifically target these glands for ablation.
Study: NCT01870882

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attentional retraining

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control condition
Study: NCT03744871

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: N95 Respirator
Description: SiTi N95 respirator with microventilator (change twice weekly and earlier as needed).
Study: NCT02244879

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: resveratrol
Description: arm resveratrol 500: 6 months of resveratrol 500 mg/day arm resveratrol 40: 6 months of resveratrol 40 mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: resveratrol
Description: arm resveratrol 500: 6 months of resveratrol 500 mg/day arm resveratrol 40: 6 months of resveratrol 40 mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: resveratrol
Description: arm resveratrol 500: 6 months of resveratrol 500 mg/day arm resveratrol 40: 6 months of resveratrol 40 mg/day
Study: NCT03274882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S95005
Description: The treatment is given in open manner. It was administered until unacceptable toxicity according to the investigator, disease progression or patient withdrawal. If a patient discontinues study treatment for reasons other than radiologic disease progression (e.g., intolerable side effects), the patient was followed for tumour response until radiologic disease progression or initiation of new anticancer therapy (whichever occurs first).
Study: NCT03021252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High intensity IEMT
Description: Training load will be the maximum inspiratory / expiratory load defined according to patient tolerance equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations / expirations (x 5 set), three times per day, during 8 weeks. External loads will be increased weekly at intervals of 10 cm H2O as tolerated. Patients will receive standard swallow therapy consisting of swallowing manoeuvres, oral exercises, and compensatory techniques aimed to improve self-management of dysphagia and protect the airway.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham IEMT
Description: 5 sets of 10 inspirations and expirations in a sham IEMT trainer, three times a day, during 8 weeks.
Study: NCT03483207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin \&warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .
Study: NCT00848419

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural administration of bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural administration of bolus
Study: NCT00848419

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural administration of bolus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epidural administration of bolus
Study: NCT02831660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarucizumab
Study: NCT03767439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: 150 mg PO daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480 mg IV every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1 mg/kg IV every 6 weeks
Study: NCT01787383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol mebutate gel 0.05 %
Description: Ingenol mebutate gel 0.05 % (Picato®) on trunk/extremities either applied simultaneously or sequentially

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol mebutate gel 0.05 %
Description: Ingenol mebutate gel 0.05 % (Picato®) on trunk/extremities either applied simultaneously or sequentially
Study: NCT02195297

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ANTICELLULITE GMG GIULIANI Cream and SOMATOLINE Cream
Description: Products application: mono-laterally, once a day at evening (4 doses from each dispenser for the first 2 day-treatment and 2 doses for the following days)
Study: NCT01787383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol mebutate gel 0.015 %
Description: Ingenol mebutate gel 0.015 % (Picato®) on face/scalp either applied simultaneously or sequentially

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol mebutate gel 0.015 %
Description: Ingenol mebutate gel 0.015 % (Picato®) on face/scalp either applied simultaneously or sequentially
Study: NCT03901638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tllsh2910
Description: Tllsh2910 80mg twice per day orally for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tllsh2910
Description: Tllsh2910 80mg twice per day orally for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT02669498

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine fallopian tube removal
Description: Fallopian tubes are removed by dissection of the Mesosalpinx.
Study: NCT04686344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intermittent boluses of Hypertonic saline
Description: intermittent boluses every 6 hours over 30 min for 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuous infusion of Hypertonic saline
Description: continuous infusion over a period of 48 hours
Study: NCT03553537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 10mg/m² iv on day 1-5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 750mg/m² iv on day 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750mg/m² iv on day 6
Study: NCT01157663

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted balance training
Description: during 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance Training
Description: Balance training with unipedal standing during 8 weeks